Sandostatin LAR ( DrugBank: - )

4 diseases

67. 多発性嚢胞腎

臨床試験数 : 216 / 薬物数 : 219 - (DrugBank : 50) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 151

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2009-017849-57-NL (EUCTR)	24/03/2011	13/01/2010	Somatostatin analogues as a volume reducing treatment of polycystic livers - SOLVE	Somatostatin analogues as a volume reducing treatment of polycystic livers - SOLVE	Polycystic liver disease, due to isolated polycystic liver disease or polycystic kidney disease. Med ...	Product Name: Sandostatin LAR Product Code: unknown Product Name: Somatuline Autosolution Product Code: ...	Radboud University Nijmegen Medical Centre	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands

臨床試験数 : 149 / 薬物数 : 227 - (DrugBank : 81) / 標的遺伝子数 : 82 - 標的パスウェイ数 : 167

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2013-005376-17-NL (EUCTR)	20/06/2014	27/02/2014	Sandostatin therapy in sarcoidosis	Sandostatin therapy in sarcoidosis - SST in SA	Sarcoidosis MedDRA version: 16.1;Level: HLGT;Classification code 10003816;Term: Autoimmune disorders ...	Trade Name: Sandostatin LAR INN or Proposed INN: OCTREOTIDE Other descriptive name: octreotide LAR / S ...	Erasmus Medical Center	NULL	Not Recruiting			Female: yes Male: yes			Netherlands

臨床試験数 : 111 / 薬物数 : 120 - (DrugBank : 30) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 103

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01613495 (ClinicalTrials.gov)	August 2005	13/4/2011	Ghrelin Suppression by Octreotide in Prader-Willi	Ghrelin Suppression by Sandostatin LAR® Depot (Octreotide Acetate for Injectable Suspension) in Pati ...	Prader Willis Syndrome	Drug: Placebo;Drug: Octreotide	Oregon Health and Science University	NULL	Active, not recruiting	18 Years	N/A	Male	2	N/A	NULL
2	NCT00175305 (ClinicalTrials.gov)	August 2004	9/9/2005	Prader-Willi Syndrome and Appetite	Effect of Somatostatin on Ghrelin Concentrations, Food Seeking Behaviour and Weight in Patients With ...	Hyperphagia;Prader-Willi Syndrome	Drug: Sandostatin LAR	University of British Columbia	NULL	Terminated	10 Years	17 Years	Both	10	Phase 3	Canada

臨床試験数 : 54 / 薬物数 : 73 - (DrugBank : 21) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 136

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-001340-19-NL (EUCTR)	21/07/2016	11/07/2016	The effectiveness of the drug octreotide LAR to anemia in patients with gastrointestinal bleeding du ...	An uncontrolled, pilot-study assessing the efficacy of octreotide LAR to decrease transfusion requir ...	Patients with Rendu-Osler-Weber disease (which is also called: Hereditary hemorrhagic telangiectasia ...	Trade Name: Sandostatin LAR 20 mg Product Name: Sandostatin LAR Product Code: RVG 18236	Radboud University Medical Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Netherlands